Description: ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Home Page: www.alk.net
BOege AllE 6-8
Horsholm,
2970
Denmark
Phone:
45 45 74 75 76
Officers
| Name | Title |
|---|---|
| Mr. Claus Steensen Solje | Executive VP, CFO & Member of Management Board |
| Mr. Søren Daniel Niegel | Executive VP of Commercial Operations & Member of Management Board |
| Dr. Henriette Mersebach | Executive VP Research & Development & Member of Management Board |
| Ms. Katja Barnkob Thalund | Project Director of Global CMC Development & Employee-elected Director |
| Ms. Lise Lund Maerkedahl | Project Director of Global Research & Employee-elected Director |
| Mr. Peter Halling | President & CEO |
| Mr. Per Plotnikof | VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR |
| Jacob Glenting | Senior Vice President of Global Strategy & Corporate Development |
| Ms. Lika Thiesen | Executive Vice President of Global People & Organisation |
| Prof. Hendrik Kees Kam Nolte M.D., Ph.D. | Senior Vice President of Research & Development - North America and International Markets |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 46.2128 |
| Price-to-Book MRQ: | 7.0514 |
| Price-to-Sales TTM: | 0.9346 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2806 |